Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Nkarta Therapeutics Appoints Regulatory Affairs VP | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Nkarta Therapeutics Appoints Regulatory Affairs VP

Lisa Arjes brings 25 years of experience in engineering, quality, project management, drug supply and regulatory affairs in the biopharma industry

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Nkarta Therapeutics has appointed Lisa Arjes as vice president of regulatory affairs and clinical quality. Ms. Arjes joins the company with 25 years of experience in engineering, quality, project management, drug supply and regulatory affairs in the biopharmaceutical industry.

“As we advance our novel NK cell therapies toward the clinic, we are pleased to have Lisa leading our regulatory affairs and quality efforts, which are growing and expanding in the organization,” said Paul Hastings, president and chief executive officer, Nkarta Therapeutics. “With Lisa’s guidance, we are planning several Investigational New Drug (IND) Applications within the next twelve months. These include two for NKX101 that will allow dose finding Phase 1 clinical trials in hematological malignancies as well as solid tumors, and an IND for our CAR19-NK program to enable us to begin clinical trials in B-cell malignancies. We believe our innovative and differentiated approach to cell therapy, using natural killer cells, will potentially offer patients a more potent, better tolerated cell therapy option.”

Lisa Arjes joins Nkarta from Revolution Medicines where she was responsible for building the company’s regulatory and quality assurance departments. Prior to Revolution Medicines, she was director of regulatory affairs at Medivation, Inc. (acquired by Pfizer) where she developed and implemented global regulatory strategies for oncology programs in all phases of development. She also held positions as associate regulatory program director and manager of clinical supply chain at Genentech, Inc. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters